Sensorineural hearing loss associated with vincristine treatment.
We describe a 64-year-old patient with multiple myeloma who developed a sudden sensorineural hearing loss shortly after receiving chemotherapy with vincristine. Ototoxicity is not a known side effect of this drug. It would be of interest to perform repeated audiograms on patients receiving vincristine, in order to appreciate the actual ototoxicity of this drug.
Lugassy
G
G
Institute of Hematology, Barzilai Medical Center, Ashkelon, Israel.
Shapira
A
A
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001299:Audiometry; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects*
D014750:Vincristine